Home > Insider Trading > Filing (0001209191-19-057850)

Filing Details

Accession Number:: 0001209191-19-057850
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-11-22 17:30:56
Reporting Period:: 2019-11-20

Accepted Time:: 2019-11-22 17:30:56
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649904	Rhythm Pharmaceuticals Inc.	RYTM	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1473930	Todd Foley	C/O Mpm Asset Management 450 Kendall Street Cambridge MA 02142		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-11-20	141,365	$22.02	2,933,528	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-11-21	59,466	$20.50	2,874,062	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-11-21	5,457	$21.09	2,868,605	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The shares were sold as follows: 136,079 by MPM BioVentures V, L.P. ("BV V") and 5,286 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $21.59 to $22.58. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Shares are held as follows: 2,823,827 by BV V and 109,701 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Shares were sold as follows: 57,242 by BV V and 2,224 by AM BV5.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.00 to $20.99. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Shares are held as follows: 2,766,585 by BV V and 107,477 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Shares were sold as follows: 5,253 by BV V and 204 by AM BV5.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $21.00 to $21.28. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Shares are held as follows: 2,761,332 by BV V and 107,273 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.